MX2021015667A - Metodo de reconstitucion de anamicina liposomica. - Google Patents
Metodo de reconstitucion de anamicina liposomica.Info
- Publication number
- MX2021015667A MX2021015667A MX2021015667A MX2021015667A MX2021015667A MX 2021015667 A MX2021015667 A MX 2021015667A MX 2021015667 A MX2021015667 A MX 2021015667A MX 2021015667 A MX2021015667 A MX 2021015667A MX 2021015667 A MX2021015667 A MX 2021015667A
- Authority
- MX
- Mexico
- Prior art keywords
- reconstitution
- anamicin
- liposomic
- methods
- anamycin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868190P | 2019-06-28 | 2019-06-28 | |
| PCT/US2020/039621 WO2020264161A1 (en) | 2019-06-28 | 2020-06-25 | Method of reconstituting liposomal annamycin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015667A true MX2021015667A (es) | 2022-04-18 |
Family
ID=74061076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015667A MX2021015667A (es) | 2019-06-28 | 2020-06-25 | Metodo de reconstitucion de anamicina liposomica. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12257262B2 (enExample) |
| EP (1) | EP3990041B1 (enExample) |
| JP (1) | JP7830131B2 (enExample) |
| KR (1) | KR20220027941A (enExample) |
| CN (2) | CN116785242A (enExample) |
| AU (2) | AU2020302784A1 (enExample) |
| BR (1) | BR112021026480A2 (enExample) |
| CA (1) | CA3144443A1 (enExample) |
| ES (1) | ES3049663T3 (enExample) |
| IL (1) | IL289433B2 (enExample) |
| MX (1) | MX2021015667A (enExample) |
| PL (1) | PL3990041T3 (enExample) |
| SG (1) | SG11202113005SA (enExample) |
| TW (2) | TW202500161A (enExample) |
| WO (1) | WO2020264161A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020264161A1 (en) | 2019-06-28 | 2020-12-30 | Donald Picker | Method of reconstituting liposomal annamycin |
| EP3989978B1 (en) | 2019-06-28 | 2025-12-17 | Board of Regents, The University of Texas System | Preparation of preliposomal annamycin lyophilizate |
| AU2020386092A1 (en) * | 2019-11-21 | 2022-06-16 | Board Of Regents, The University Of Texas System | Lung targeted anticancer therapies with liposomal annamycin |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4927571A (en) | 1987-05-18 | 1990-05-22 | Liposome Technology, Inc. | Preparation of injectable doxorubicin/liposome suspension |
| US4863739A (en) | 1987-05-19 | 1989-09-05 | Board Of Regents, The University Of Texas System | Liposome compositions of anthracycline derivatives |
| IS1685B (is) * | 1990-12-11 | 1998-02-24 | Bracco International B.V. | Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum |
| US5902604A (en) | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
| WO2001032145A1 (en) * | 1999-10-29 | 2001-05-10 | Board Of Regents, The University Of Texas System | Method of cancer treatment |
| AU2004212944B2 (en) * | 2003-02-14 | 2008-08-21 | Children's Hospital & Research Center At Oakland | Lipophilic drug delivery vehicle and methods of use thereof |
| US20130045937A1 (en) * | 2010-03-10 | 2013-02-21 | Cempra Pharmaceuticals, Inc. | Parenteral formulations of macrolide antibiotics |
| PT4241849T (pt) * | 2011-10-14 | 2024-10-30 | Hoffmann La Roche | Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo |
| KR102284689B1 (ko) * | 2011-10-21 | 2021-08-02 | 셀라토 파마슈티칼즈, 인코포레이티드 | 동결건조된 리포좀 |
| US8926994B2 (en) | 2011-12-07 | 2015-01-06 | The Methodist Hospital Research Institute | Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity |
| WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| CN107569508A (zh) * | 2016-07-05 | 2018-01-12 | 江苏竞诺择生物医药科技有限公司 | 一种治疗造血系统增殖性疾病的药用组合物 |
| AU2017324718B2 (en) * | 2016-09-09 | 2022-09-29 | Irisys, Inc. | Lipsomal anticancer compositions |
| WO2019023873A1 (zh) * | 2017-07-31 | 2019-02-07 | 江苏竞诺择生物医药科技有限公司 | 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物 |
| UA129837C2 (uk) | 2018-09-04 | 2025-08-20 | Мінерва Ньюросаєнсиз, Інк. | Способи застосування феноксипропіламінової сполуки для лікування болю |
| WO2020264161A1 (en) | 2019-06-28 | 2020-12-30 | Donald Picker | Method of reconstituting liposomal annamycin |
| EP3989978B1 (en) | 2019-06-28 | 2025-12-17 | Board of Regents, The University of Texas System | Preparation of preliposomal annamycin lyophilizate |
| AU2020386092A1 (en) | 2019-11-21 | 2022-06-16 | Board Of Regents, The University Of Texas System | Lung targeted anticancer therapies with liposomal annamycin |
-
2020
- 2020-06-25 WO PCT/US2020/039621 patent/WO2020264161A1/en not_active Ceased
- 2020-06-25 ES ES20832031T patent/ES3049663T3/es active Active
- 2020-06-25 PL PL20832031.7T patent/PL3990041T3/pl unknown
- 2020-06-25 JP JP2021577862A patent/JP7830131B2/ja active Active
- 2020-06-25 CN CN202310738252.3A patent/CN116785242A/zh active Pending
- 2020-06-25 CN CN202080048890.7A patent/CN114728101B/zh active Active
- 2020-06-25 IL IL289433A patent/IL289433B2/en unknown
- 2020-06-25 BR BR112021026480A patent/BR112021026480A2/pt unknown
- 2020-06-25 SG SG11202113005SA patent/SG11202113005SA/en unknown
- 2020-06-25 AU AU2020302784A patent/AU2020302784A1/en active Pending
- 2020-06-25 KR KR1020227000486A patent/KR20220027941A/ko active Pending
- 2020-06-25 EP EP20832031.7A patent/EP3990041B1/en active Active
- 2020-06-25 CA CA3144443A patent/CA3144443A1/en active Pending
- 2020-06-25 MX MX2021015667A patent/MX2021015667A/es unknown
- 2020-06-29 TW TW113132623A patent/TW202500161A/zh unknown
- 2020-06-29 TW TW109121840A patent/TWI857086B/zh active
-
2021
- 2021-12-17 US US17/554,553 patent/US12257262B2/en active Active
-
2023
- 2023-10-05 US US18/481,951 patent/US11980634B2/en active Active
-
2024
- 2024-05-29 AU AU2024203593A patent/AU2024203593B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202113005SA (en) | 2021-12-30 |
| ES3049663T3 (en) | 2025-12-17 |
| CN116785242A (zh) | 2023-09-22 |
| IL289433A (en) | 2022-02-01 |
| TW202114704A (zh) | 2021-04-16 |
| IL289433B2 (en) | 2026-05-01 |
| BR112021026480A2 (pt) | 2022-02-08 |
| AU2020302784A1 (en) | 2022-01-20 |
| US20220105116A1 (en) | 2022-04-07 |
| US11980634B2 (en) | 2024-05-14 |
| IL289433B1 (en) | 2026-01-01 |
| CN114728101A (zh) | 2022-07-08 |
| WO2020264161A1 (en) | 2020-12-30 |
| TW202500161A (zh) | 2025-01-01 |
| US12257262B2 (en) | 2025-03-25 |
| PL3990041T3 (pl) | 2026-02-23 |
| CN114728101B (zh) | 2023-07-14 |
| JP2023523872A (ja) | 2023-06-08 |
| EP3990041A1 (en) | 2022-05-04 |
| AU2024203593B2 (en) | 2025-08-14 |
| EP3990041A4 (en) | 2023-07-12 |
| CA3144443A1 (en) | 2020-12-30 |
| EP3990041B1 (en) | 2025-08-06 |
| JP7830131B2 (ja) | 2026-03-16 |
| TWI857086B (zh) | 2024-10-01 |
| AU2024203593A1 (en) | 2024-07-11 |
| US20240024345A1 (en) | 2024-01-25 |
| KR20220027941A (ko) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY205856A (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
| MX2022003930A (es) | Conjugados de péptido de camptotecina. | |
| EA201992781A1 (ru) | Ингибиторы g12c kras и способы их применения | |
| MX2025010681A (es) | Formulaciones transdermicas | |
| MX2026000462A (es) | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de estos | |
| EA201991455A1 (ru) | Композиции и способы лечения дефицита альфа-1-антитрипсина | |
| PH12019502341A1 (en) | Compositions and methods involving probiotic molecules | |
| MX2023009681A (es) | Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon. | |
| MX2020010836A (es) | Inhibidores de kras g12c y métodos para su uso. | |
| BR112019007210A2 (pt) | métodos e composições para o tratamento da doença de fabry | |
| MY190411A (en) | Improved uricase sequences and methods of treatment | |
| MX2020006297A (es) | Variantes de cd19. | |
| ZA202103975B (en) | Methods of treating disease with magl inhibitors | |
| ECSP20083339A (es) | Proteínas inmunodominantes y fragmentos en esclerosis múltiple | |
| MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
| WO2021191689A3 (en) | Treatment of inflammatory diseases with peptides and pharmaceutical compositions | |
| EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека | |
| EP4295903A3 (en) | Compositions and methods for treating farber disease | |
| CY1124679T1 (el) | Μεθοδος μειωσης η απενεργοποιησης του ιικου και μικροβιακου περιεχομενου στις μεθοδους παρασκευης παγκρεατινης | |
| JOP20220007A1 (ar) | طرق للعلاج أو الوقاية من ضمور العضلات النخاعي | |
| PH12020551146A1 (en) | Methods for treating farber disease | |
| MX2021008865A (es) | Inhibidores de magl para usarse para tratar enfermedades antecedentes. | |
| JOP20230034A1 (ar) | مثبطات إفراز البروتين | |
| IL289242A (en) | Combination therapy methods, compositions and kits | |
| EA202092540A1 (ru) | Комбинации для лечения рака |